Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells
Tech ID: 33619 / UC Case 2020-221-0

TECHNOLOGY DESCRIPTION

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body’s natural immune response against these malignant cells. The inventors have developed a novel therapeutic approach that uses anti-CD94 antibodies to deplete NK cells in a cancer patient.

APPLICATION

This method enhances the targeting and killing of cancer cells by activated T cells, such as CD8+ effector T cells. The anti-CD94 antibodies can be administered in conjunction with other therapies like checkpoint inhibitors and antigen administration for cancer antigens. The antibodies can also be used to reduce an NK cell-mediated immune response to non-self cells or tissues transplanted in an individual, thereby enhancing the effectiveness of therapies such as CAR-T cell therapy.

DATA AVAILABILITY

The inventors have shown specific binding regions and potential for high affinity binding to CD94.

PATENT STATUS

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td>Published Application</td>
<td>116829185</td>
<td>04/05/2024</td>
<td>2020-221</td>
</tr>
</tbody>
</table>

Additional Patents Pending